| Tisagenlecleucel studied in …STUDIED_INderived42 of 42show fewer |
|---|
| → studied in | NCT04094311Phase 3 · recruiting Study of Out of Specification for Tisagenlecleucel · 42 trials list this drug (9 active) | — | — | B Acute Lymphoblastic Leukemia,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06408194Phase 1 · recruiting Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies · 42 trials list this drug (9 active) | — | — | Leukemia,Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03876769Phase 2 · active not recruiting Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients · 42 trials list this drug (9 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05075603Phase 1 · completed Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03568461Phase 2 · completed Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma · 42 trials list this drug (9 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07676877Phase 1 · not yet recruiting Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03601442available Managed Access Programs for CTL019, Tisagenlecleucel · 42 trials list this drug (9 active) | — | — | Leukemia,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05888493Phase 3 · active not recruiting A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma · 42 trials list this drug (9 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460533Phase 2 · active not recruiting A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) · 42 trials list this drug (9 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03642626Phase 2 · active not recruiting MT2017-45: CAR-T Cell Therapy for Heme Malignancies · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04855253Phase 1/Phase 2 · suspended Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04134117Phase 1 · completed Tisagenlecleucel In Primary CNS Lymphoma · 42 trials list this drug (9 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04890236early Phase 1 · completed Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06101381Phase 1/Phase 2 · recruiting CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03610724Phase 2 · completed Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients · 42 trials list this drug (9 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02445248Phase 2 · completed Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02435849Phase 2 · completed Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients · 42 trials list this drug (9 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03896854Phase 1/Phase 2 · unknown CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) · 42 trials list this drug (9 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01029366Phase 1 · completed CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy · 42 trials list this drug (9 active) | — | — | Adult Acute Lymphoblastic Leukemia,Chronic Lymphocytic Leukemia,Prolymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01747486Phase 2 · completed Dose Optimization Trial of CD19 Redirected Autologous T Cells · 42 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02030834Phase 2 · completed Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas · 42 trials list this drug (9 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02030847Phase 2 · completed Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia · 42 trials list this drug (9 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02640209early Phase 1 · terminated Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) · 42 trials list this drug (9 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02935543Phase 2 · terminated CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04161118Phase 2 · terminated TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma · 42 trials list this drug (9 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04156659Phase 2 · withdrawn Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL · 42 trials list this drug (9 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03876028Phase 1 · terminated Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04225676Phase 2 · terminated Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03630159Phase 1 · completed Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02529813Phase 1 · completed CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04456023Phase 2 · withdrawn Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) · 42 trials list this drug (9 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03123939Phase 3 · completed Phase III B in Acute Lymphoblastic Leukemia · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02906371Phase 1 · completed Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02228096Phase 2 · completed Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients · 42 trials list this drug (9 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01551043Phase 1 · terminated Allo CART-19 Protocol · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03628053Phase 3 · withdrawn Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01626495Phase 1/Phase 2 · completed Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma · 42 trials list this drug (9 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03101709Phase 1 · unknown The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma · 42 trials list this drug (9 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02167360Phase 2 · withdrawn Study of Efficacy and Safety of CTL019 in Adult ALL Patients · 42 trials list this drug (9 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03027739Phase 2/Phase 3 · unknown CART-19 Cells For MRD Positive CD19+ ALL · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02810223Phase 1 · unknown Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia · 42 trials list this drug (9 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |